September 23rd, 2015 – The Grosseto hospital brings home another success in the field of international medical research. A study that involved over 8,000 patients (in 78 hospitals across Italy, Holland, Switzerland, Belgium, Spain and Sweden) was in part coordinated by the Hemodynamics Center of Grosseto, which focused on the “Matrix-OCT” substudy associated with the research. The results were published by two major magazines world of medicine, the New England Journal of Medicine and The Lancet, and at the end of August were presented in London, during the European Cardiology Congress, the largest in the world with over 30,000 professionals. Matrix (an acronym for Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX Program) studied patients undergoing coronary angioplasty, comparing two different methods – access through the radial artery or the femoral artery – and the use of two anticoagulant drugs used during the angioplasty: bivalirudin and heparin. The study – as stated in a note of the Grosseto USL 9 – demonstrated the clear superiority of radial access, used for years by the Hemodynamics Center of the Misericordia Hospital in Grosseto, and the partial superiority of the use of bivalirudin (less bleeding and less mortality but in combination with an increase in acute occlusion of the stent) that had already been the subject of a research conducted in Grosseto on 200 patients and published in October 2009, in the American Journal of Cardiology. Overall, it’s another triumph for the Grosseto hospital, for the role it had in the study – since the director of the Hemodynamics Center, Ugo Limbruno, is also co-author of the published articles – and that will continue to operate as a European coordination center for the Matrix- OCT substudy, for which Andrea Picchi is “principal investigator”. (Red)
